Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/19/24
End: 05/01/26
Due: 05/01/27
Phase: N/A
Priority: Normal
Start: 03/29/21
End: 06/02/22
Due: 06/02/23
Phase: N/A
Priority: Normal
Start: 11/06/23
End: 09/20/24
Due: 09/20/25
Phase: N/A
Priority: Normal
Start: 10/20/23
End: 01/31/25
Due: 01/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer | NCT06754085 | HTA Co., Ltd. | user2@example.com | None | 2024-12-19 | 2026-05-01 | 2027-05-01 | - | - | 2025-07-14 |
| Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT | NCT05614518 | HTA Co., Ltd. | user2@example.com | None | 2021-03-29 | 2022-06-02 | 2023-06-02 | - | - | 2025-07-14 |
| A Phase I Clinical Study on the Safety and Pharmacokinetics of [18F]Florbetazine Injection | NCT06593626 | HTA Co., Ltd. | user2@example.com | None | 2023-11-06 | 2024-09-20 | 2025-09-20 | - | - | 2025-07-14 |
| Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer | NCT06011304 | HTA Co., Ltd. | user2@example.com | None | 2023-10-20 | 2025-01-31 | 2026-01-31 | - | - | 2025-07-14 |